Targeting USP9X–AMPK Axis in ARID1A-Deficient Hepatocellular Carcinoma

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is a highly heterogeneous solid tumor with high morbidity and mortality. AT-rich interaction domain 1A (ARID1A) accounts for up to 10% of mutations in liver cancer, however, its role in HCC remains controversial, and no targeted therapy has been...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Feng-Kun, Ni, Qian-Zhi, Wang, Kang, Cao, Hui-Jun, Guan, Dong-Xian, Zhang, Er-Bin, Ma, Ning, Wang, Yi-Kang, Zheng, Qian-Wen, Xu, Sheng, Zhu, Bing, Chen, Tian-Wei, Xia, Ji, Qiu, Xiao-Song, Ding, Xu-Fen, Jiang, Hao, Qiu, Lin, Wang, Xiang, Chen, Wei, Cheng, Shu-Qun, Xie, Dong, Li, Jing-Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9117818/
https://www.ncbi.nlm.nih.gov/pubmed/35390516
http://dx.doi.org/10.1016/j.jcmgh.2022.03.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9117818/
https://www.ncbi.nlm.nih.gov/pubmed/35390516
http://dx.doi.org/10.1016/j.jcmgh.2022.03.009

Ejemplares similares